Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce

Dow Jones08-06 06:20

Pacific Biosciences of California named Chief Operating Officer Mark Van Oene to helm the company as chief executive officer.

The life science technology company also said Wednesday it would cut about 8% of its workforce, or 40 employees, under a new restructuring plan.

Van Oene succeeds Christian Henry, who has stepped down as CEO and president after six years. Henry will continue on the board and has agreed to stay on as an adviser at least through the end of 2026 to facilitate the transition, the company said.

PacBio said Van Oene's appointment to the roles of CEO and president, as well as to its board, takes effect Wednesday. Van Oene joined PacBio in 2021.

The company said it expects its restructuring plan, which was approved by the board last week, to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027.

The company expects to incur pre-tax charges of about $2 million in connection with the layoffs, primarily consisting of severance payments, employee benefits, outplacement services and related costs. It expects the restructuring will be completed and that the charges will be incurred in the third quarter.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657323574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657323574","market":"nz","top_or_hot":-1,"title":"Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pacific Biosciences of California named Chief Operating Officer Mark Van Oene to helm the company as chief executive officer. \n</p>\n<p>\n  The life science technology company also said Wednesday it would cut about 8% of its workforce, or 40 employees, under a new restructuring plan. \n</p>\n<p>\n  Van Oene succeeds Christian Henry, who has stepped down as CEO and president after six years. Henry will continue on the board and has agreed to stay on as an adviser at least through the end of 2026 to facilitate the transition, the company said. \n</p>\n<p>\n  PacBio said Van Oene's appointment to the roles of CEO and president, as well as to its board, takes effect Wednesday. Van Oene joined PacBio in 2021. \n</p>\n<p>\n  The company said it expects its restructuring plan, which was approved by the board last week, to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027. \n</p>\n<p>\n  The company expects to incur pre-tax charges of about $2 million in connection with the layoffs, primarily consisting of severance payments, employee benefits, outplacement services and related costs. It expects the restructuring will be completed and that the charges will be incurred in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-06 06:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pacific Biosciences of California named Chief Operating Officer Mark Van Oene to helm the company as chief executive officer. \n</p>\n<p>\n  The life science technology company also said Wednesday it would cut about 8% of its workforce, or 40 employees, under a new restructuring plan. \n</p>\n<p>\n  Van Oene succeeds Christian Henry, who has stepped down as CEO and president after six years. Henry will continue on the board and has agreed to stay on as an adviser at least through the end of 2026 to facilitate the transition, the company said. \n</p>\n<p>\n  PacBio said Van Oene's appointment to the roles of CEO and president, as well as to its board, takes effect Wednesday. Van Oene joined PacBio in 2021. \n</p>\n<p>\n  The company said it expects its restructuring plan, which was approved by the board last week, to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027. \n</p>\n<p>\n  The company expects to incur pre-tax charges of about $2 million in connection with the layoffs, primarily consisting of severance payments, employee benefits, outplacement services and related costs. It expects the restructuring will be completed and that the charges will be incurred in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657323574","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657323574","pubTimestamp":1785968400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pacific Biosciences of California named Chief Operating Officer Mark Van Oene to helm the company as chief executive officer.The life science technology company also said Wednesday it would cut about 8% of its workforce, or 40 employees, under a new restructuring plan.Van Oene succeeds Christian Henry, who has stepped down as CEO and president after six years. Henry will continue on the board and has agreed to stay on as an adviser at least through the end of 2026 to facilitate the transition, the company said.PacBio said Van Oene's appointment to the roles of CEO and president, as well as to its board, takes effect Wednesday. Van Oene joined PacBio in 2021.The company said it expects its restructuring plan, which was approved by the board last week, to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027.The company expects to incur pre-tax charges of about $2 million in connection with the layoffs, primarily consisting of severance payments, emplo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","PACB":"Pacific Biosciences of Californi","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"加州太平洋生物科学公司任命新首席执行官，计划裁员 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACB":1.5},"content_text":"Pacific Biosciences of California named Chief Operating Officer Mark Van Oene to helm the company as chief executive officer. \n\n\n  The life science technology company also said Wednesday it would cut about 8% of its workforce, or 40 employees, under a new restructuring plan. \n\n\n  Van Oene succeeds Christian Henry, who has stepped down as CEO and president after six years. Henry will continue on the board and has agreed to stay on as an adviser at least through the end of 2026 to facilitate the transition, the company said. \n\n\n  PacBio said Van Oene's appointment to the roles of CEO and president, as well as to its board, takes effect Wednesday. Van Oene joined PacBio in 2021. \n\n\n  The company said it expects its restructuring plan, which was approved by the board last week, to reduce its annualized operating expenses by $30 million to $40 million by the end of 2027. \n\n\n  The company expects to incur pre-tax charges of about $2 million in connection with the layoffs, primarily consisting of severance payments, employee benefits, outplacement services and related costs. It expects the restructuring will be completed and that the charges will be incurred in the third quarter.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657323574","isCrawlerRequest":true}